Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0W8SB
|
||||
| Former ID |
DAP000938
|
||||
| Drug Name |
Penbutolol
|
||||
| Synonyms |
Betapressin; Levatol; Levatolol; Levopenbutol; Lobeta; Paginol; Penbutololum; PENBUTOLOL SULFATE; HOE 893; HOE 893d; Betapressin (TN); Hostabloc (TN); L-Penbutolol; Levatol (TN); Levatolol (TN); Lobeta (TN); Paginol (TN); Penbutolol (INN); Penbutolol [INN:BAN]; Penbutololum [INN-Latin]; Penbutolol Sulfate (2:1); S(-)-Penbutolol; (-)-Penbutolol; (2S)-1-(tert-butylamino)-3-(2-cyclopentylphenoxy)propan-2-ol; 1-(tert-Butylamino)-3-(o-cyclopentylphenoxy)propan-2-ol
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Hypertension; Angina pectoris [ICD9: 401, 413; ICD10:I10-I16, I20] | Approved | [1], [2], [3] | ||
| Therapeutic Class |
Antihypertensive Agents
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C18H29NO2
|
||||
| InChI |
InChI=1S/C18H29NO2/c1-18(2,3)19-12-15(20)13-21-17-11-7-6-10-16(17)14-8-4-5-9-14/h6-7,10-11,14-15,19-20H,4-5,8-9,12-13H2,1-3H3/t15-/m0/s1
|
||||
| InChIKey |
KQXKVJAGOJTNJS-HNNXBMFYSA-N
|
||||
| CAS Number |
CAS 36507-48-9
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9620, 8175027, 15902888, 34678763, 46504929, 47291267, 47589134, 48416387, 50022970, 50064728, 57312048, 77621769, 96024764, 103293389, 103400617, 104326642, 117556859, 124954107, 128421871, 134223256, 134338213, 134999314, 135049302, 137001394, 142047536, 160964648, 175266991, 178103837, 179150414, 223440604, 226426442
|
||||
| SuperDrug ATC ID |
C07AA23
|
||||
| SuperDrug CAS ID |
cas=036507489
|
||||
| Target and Pathway | |||||
| Target(s) | Beta-1 adrenergic receptor | Target Info | Antagonist | [4], [5] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| cGMP-PKG signaling pathway | |||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Endocytosis | |||||
| Adrenergic signaling in cardiomyocytes | |||||
| Gap junction | |||||
| Salivary secretion | |||||
| Dilated cardiomyopathy | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Beta1 adrenergic receptor signaling pathway | |||||
| PathWhiz Pathway | Muscle/Heart Contraction | ||||
| Reactome | Adrenoceptors | ||||
| G alpha (s) signalling events | |||||
| WikiPathways | Monoamine GPCRs | ||||
| Calcium Regulation in the Cardiac Cell | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Endothelin Pathways | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Penbutolol and carteolol: two new beta-adrenergic blockers with partial agonism. J Clin Pharmacol. 1990 May;30(5):412-21. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7263). | ||||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
| REF 4 | beta-Adrenergic receptor blockers--a group of chiral drugs: different effects of each enantiomer. Ceska Slov Farm. 2002 May;51(3):121-8. | ||||
| REF 5 | Decrease in penbutolol central response as a cause of changes in its serum protein binding. J Pharm Pharmacol. 1990 Mar;42(3):164-6. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.